Legend Biotech (LEGN) reported Tuesday a Q4 adjusted net loss of $0.15 per diluted share, narrower than its loss of $0.24 per share a year earlier.
Analysts polled by FactSet expected a loss of $0.25.
Revenue for the quarter ended Dec. 31 was $186.5 million, up from $79.5 million a year earlier.
Analysts surveyed by FactSet expected $178.1 million.
As of Dec. 31, the company said it had approximately $1.1 billion of cash and cash equivalents and time deposits, and expected it could fund operations through Q2 of fiscal 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。